Eli Lilly's experimental weight‑loss pill orforglipron shows promise
Eli Lilly's oral GLP‑1 candidate orforglipron helped trial participants with type 2 diabetes lose about 8% of body weight and lower A1C, offering a potential needle‑free alternative to injectable drugs.
Key points
- In a Phase trial, participants lost nearly 8% of body weight while taking oral orforglipron.
- The pill also produced significant reductions in A1C levels for people with type 2 diabetes.
- Common side effects were mild to moderate digestive issues such as nausea and diarrhea.
- Eli Lilly plans to seek FDA approval for diabetes use this year and global weight‑management approval by year‑end.
Eli Lilly is making headlines with its experimental GLP-1 weight loss pill, orforglipron, which could soon offer a needle-free alternative to popular injectable drugs like Ozempic and Mounjaro. In a recent Phase trial, people with type diabetes taking orforglipron lost an average of nearly 8% of their body weight—about pounds—over weeks. The pill also significantly lowered A1C levels, a key marker for diabetes control.
Unlike current oral GLP-1 options, orforglipron does not require strict food or water restrictions, making it more convenient for patients. The most common side effects reported were mild to moderate digestive issues, such as nausea and diarrhea, similar to those seen with injectable GLP-1 drugs.
Eli Lilly plans to seek FDA approval for orforglipron as a diabetes treatment in and aims to pursue global approval for weight management by the end of this year. If approved, the company expects to launch the pill without the supply constraints that have plagued injectable GLP-1 medications.
Analysts believe orforglipron could be as effective as current injectable treatments, potentially reshaping the booming weight loss drug market and making these therapies more accessible to millions who prefer pills over injections.
Your questions, answered
What weight loss results did Eli Lilly's orforglipron achieve in trials?
Trial participants lost an average of about 8% of their body weight while taking the oral pill.
How does orforglipron differ from existing GLP‑1 treatments?
It is taken as a pill, does not require strict food or water restrictions, and aims to avoid the supply constraints of injectable GLP‑1 drugs.
Quick poll
Should oral GLP‑1 pills be prioritized over injectable options for weight loss?
0 votes
How does this story make you feel?
Topics
Up next · HealthUSC Speak Your Mind Challenge revives ice bucket trend for mental health
